MARKET

THAR

THAR

Tharimmune Inc
NASDAQ
4.140
+0.210
+5.34%
After Hours: 4.280 +0.14 +3.38% 19:50 02/06 EST
OPEN
4.160
PREV CLOSE
3.930
HIGH
4.200
LOW
3.995
VOLUME
1.10M
TURNOVER
--
52 WEEK HIGH
9.08
52 WEEK LOW
0.9520
MARKET CAP
234.03M
P/E (TTM)
-1.0075
1D
5D
1M
3M
1Y
5Y
1D
Tharimmune strengthens leadership and governance for Canton strategy
TipRanks · 17h ago
Tharimmune names Mark Wendland board chair, appoints Angela Radkowski as COO
Seeking Alpha · 17h ago
BUZZ-Tharimmune rises after naming new chairman, COO
Reuters · 17h ago
Tharimmune appoints Angela Radkowski as COO
TipRanks · 17h ago
Tharimmune Elects Mark Wendland As Chairman Of The Board, Succeeding Vincent LoPriore; Names Angela Radkowski COO
Benzinga · 17h ago
Tharimmune Inc. Names Mark Wendland Chairman and Angela Radkowski COO
Reuters · 17h ago
*Tharimmune, Inc. Appoints Mark Wendland Chairman Of The Board And Names Angela Radkowski Chief Operating Officer >THAR
Dow Jones · 17h ago
Tharimmune Adds New Directors to Support Digital Strategy
TipRanks · 4d ago
More
About THAR
Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutic candidates for inflammatory and immunologic conditions with unmet need. It has a transmucosal film product, TH104, is a Phase II ready clinical candidate and an oral biologic as well as two bispecific biologics in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology targets including human epidermal growth factor receptor 2, human EGF receptor 3 and programmed cell death protein. The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates, among others.

Webull offers Tharimmune Inc stock information, including NASDAQ: THAR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, THAR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading THAR stock methods without spending real money on the virtual paper trading platform.